Table 2.
Laboratory parameters.
| Control group(n=20) | Abciximab group(n=20) | Tirofiban group(n=20) | P value | |
|---|---|---|---|---|
| Haemoglobin at T0 | 8.75±0.76 | 8.66±0.69 | 8.63±0.68 | 0.68 |
| Haemoglobin at T1 | 7.99±0.73 | 7.87±0.85 | 7.99±0.74 | 0.39 |
| Haemoglobin at T2 | 8.47±0.75 | 8.46±0.82 | 8.29±0.63 | 0.65 |
| Haemoglobin at T3 | 8.49±0.68 | 8.48±0.73 | 8.42±0.76 | 0.34 |
| Haemoglobin at T4 | 8.50±0.66 | 8.41±0.72 | 8.39±0.97 | 0.49 |
| Platelet count at T0 | 235.8±45.7 | 264.3±97.9 | 268.2±42.3 | 0.46 |
| Platelet count at T1 | 209.9±40.8 | 227.1±96.4 | 248.4±30.0 | 0.51 |
| Platelet count at T2 | 219.5±45.0 | 228.7±102.0 | 258.7±34.7 | 0.32 |
| Platelet count at T3 | 219.9±44.0 | 232.7±88.5 | 261.8±38.9 | 0.27 |
| Platelet count at T4 | 222.9±46.5 | 246.7±93.6 | 256.9±42.3 | 0.62 |
| TAT at T0 | 6.23±15.12 | 4.90±9.23 | 5.14±7.55 | 0.32 |
| TAT at T1 | 11.06±24.68 | 13.68±27.63 | 8.88±7.21 | 0.31 |
| TAT at T2 | 3.35±3.37 | 3.75±3.63 | 5.12±4.13 | 0.31 |
| TAT at T3 | 5.18±13.37 | 3.22±2.73 | 4.70±4.03 | 0.39 |
| TAT at T4 | 2.20±1.99 | 5.62±8.39 | 6.70±7.79 | 0.33 |
| International normalised ratio at T0 | 1.11±0.099 | 1.11±0.091 | 1.11±0.097 | 0.54 |
| International normalised ratio at T4 | 1.14±0.122 | 1.13±0.071 | 1.17±0.178 | 0.17 |
| Prothrombin time at T0 | 17.08±3.90 | 20.14±10.33 | 16.49±2.09 | 0.40 |
| Prothrombin time at T4 | 15.70±0.89 | 17.32±5.49 | 16.97±2.63 | 0.27 |
| GP IIb/IIIa receptor genotype | ||||
| - A1/A1 | 15 | 14 | 13 | 0.79 |
| - A1/A2 | 5 | 5 | 6 | 0.92 |
| - A2/A2 | 0 | 1 | 1 | 0.60 |
| Cholesterol | 4.99±1.07 | 5.02±0.88 | 5.22±1.08 | 0.48 |
Data are presented as the absolute number of patients or mean value ± SD. TAT= thrombin-antithrombin, T0= pre-PCI, T1= directly after PCI, T2= 30 minutes after PCI, T3= 60 minutes after PCI, T4= 90 minutes after PCI.